Notice of Proposed Sale · 144

Stoke Therapeutics, Inc.

STOKNASDAQEQUITYCurrent

Notice of Proposed Sale

Filed Oct 2, 2026Accepted Oct 2, 2026, 4:20 PM EDTFiling CIK 1966716Accession 0001950047-26-010004

View company →Permanent SEC source ↗

Structured filing — 144

primary_doc.xml

Open full document ↗

Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.

Proposed-sale notice

Issuer: Stoke Therapeutics, Inc.
Issuer CIK: 0001623526
SEC file number: 001-38938
Phone: 7814308200
Person for whose account securities are to be sold: JONATHAN D ALLAN
Relationships to issuer: Officer
Street: 45 Wiggins Ave
City: Bedford
State / country code: MA
Postal code: 01730

Securities proposed for sale

Securities proposed for sale · 1 reported row
Security	Proposed units	Aggregate market value	Units outstanding	Approximate sale date	Exchange	Broker / market maker
Common	627	16,308.27	64,526,242	10/02/2026	NASDAQ	Morgan Stanley Smith Barney LLC Executive Financial Services

Broker / market maker — proposed row 1, entry 1

Name: Morgan Stanley Smith Barney LLC Executive Financial Services
Street: 1 New York Plaza
Street (continued): 8th Floor
City: New York
State / country code: NY
Postal code: 10004

Acquisition of securities to be sold

Acquisition of securities to be sold · 1 reported row
Security	Acquired	Nature of acquisition	Acquired from	Amount acquired	Gift transaction	Payment date	Nature of payment
Common	09/30/2026	Restricted Stock Units	Issuer	627	N	09/30/2026	N/A

Sales reported in the preceding three months

Sales reported in the preceding three months · 1 reported row
Seller	Security	Sale date	Amount sold	Gross proceeds
JONATHAN D ALLAN	Common	08/18/2026	2,861	91,639.43

Seller — prior-sale row 1, entry 1

Name: JONATHAN D ALLAN
Street: 45 Wiggins Ave
City: Bedford
State / country code: MA
Postal code: 01730

Prior-sale reporting

Nothing to report for the preceding three months: N

Notice signature

Notice date: 10/02/2026
Signed: /s/ Jonathan Allen
Plan adoption dates: 11/10/2025

Company context

Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine. Using Stoke’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore naturally-occurring protein levels. Stoke’s first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is currently being evaluated in a Phase 3 study. Stoke’s initial focus are diseases of the central nervous system and the eye that are caused by a loss of ~50% of normal

Current securities

STOKNASDAQ · EQUITY · Current

Free Registration